INS and Hypoglycemia: Compared to baseline the use of sulfonylureas in patients with hypoglycaemia was strongly reduced (-25.9%), while in a significant proportion of patients DPP-4 inhibitors (+26.8%), GLP-1 analogs (+7.6%) and insulins (+26.6%) were introduced (Figure 2).